However, except from a handful of known genetic aberrations such as EGFR mutations and anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement, no subgroups of NSCLC are stratified for optimized treatment based on the molecular profile of the tumor. Here, ALK is linked to non-small cell lung carcinoma.